New Reference: Zanubrutinib in CLL

Study

Open-label, multicentre, phase 3 study

Untreated CLL or SLL

Patients without del (17) (p13·1)  zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1) zanubrutinib

Efficacy

mPFS was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 – 0·63]; p<0·0001)

24 months PFS: 85·5% in group A and 69·5% in group B

ORR: 94·6% in group A and 85·3% in group B

CR rate: 7% in group A and 15% in group B

Safety

Grade 1-2 any AEs: 41% vs 16% (group A vs group B)

Grade ≥3 AEs neutropenia 11% vs 51%, infections 16% vs 19%

Grade 1-2 all bleeding AE: 41% vs 9%

Lancet Oncol. 2022 Aug;23(8):1031-1043

{“Constantine S.T etal.”}Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

http://doi.org/10.1016/s1470-2045(22)00293-5

Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022